Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

The Word Brain 2015Free PDF | Print | Web
A short guide to fast language learning

Free Abstracts

  Malignant Melanoma

  Free Subscription


1 Ann Surg Oncol
2 Anticancer Res
1 BMC Cancer
1 Br J Dermatol
1 Cancer Lett
1 Cancer Res
2 Gene
1 J Am Acad Dermatol
1 J Invest Dermatol
1 J Surg Oncol
1 Lancet Oncol
2 Melanoma Res
2 Ophthalmology
4 PLoS One
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Text format
Single Articles

    Ann Surg Oncol

  1. MOSQUERA C, Vora HS, Vohra N, Fitzgerald TL, et al
    Population-Based Analysis of Completion Lymphadenectomy in Intermediate-Thickness Melanoma.
    Ann Surg Oncol. 2016.
    PubMed     Text format     Abstract available

    Anticancer Res

  2. Melanoma.
    Anticancer Res. 2016;36:4377.
    PubMed     Text format    

  3. Genetics of Melanoma.
    Anticancer Res. 2016;36:4374.
    PubMed     Text format    

    BMC Cancer

  4. ANGELINO G, De Pasquale MD, De Sio L, Serra A, et al
    NRAS(Q61K) mutated primary leptomeningeal melanoma in a child: case presentation and discussion on clinical and diagnostic implications.
    BMC Cancer. 2016;16:512.
    PubMed     Text format     Abstract available

    Br J Dermatol

  5. WILLIS CM, Britton LE, Swindells MA, Jones EM, et al
    Invasive melanoma in-vivo can be distinguished from basal cell carcinoma, benign naevi and healthy skin by canine olfaction: a proof of principle study of differential volatile organic compound emission.
    Br J Dermatol. 2016 Jul 25. doi: 10.1111/bjd.14887.
    PubMed     Text format     Abstract available

    Cancer Lett

  6. XU S, Wang H, Pan H, Shi Y, et al
    ANRIL lncRNA triggers efficient therapeutic efficacy by reprogramming the aberrant INK4-hub in melanoma.
    Cancer Lett. 2016 Jul 25. pii: S0304-3835(16)30441.
    PubMed     Text format     Abstract available

    Cancer Res

  7. CONERY AR, Centore RC, Spillane KL, Follmer NE, et al
    Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic Response.
    Cancer Res. 2016;76:1313-9.
    PubMed     Text format     Abstract available


  8. CHEN X, Yang M, Hao W, Han J, et al
    Differentiation-inducing and anti-proliferative activities of isoliquiritigenin and all-trans-retinoic acid on B16F0 melanoma cells: Mechanisms profiling by RNA-seq.
    Gene. 2016 Jul 23. pii: S0378-1119(16)30589-3. doi: 10.1016/j.gene.2016.
    PubMed     Text format     Abstract available

  9. BANERJEE A, Ray S
    Structural insight with mutational impact on tyrosinase and PKC-beta interaction from Homo sapiens: Molecular modeling and docking studies for melanogenesis, albinism and increased risk for melanoma.
    Gene. 2016 Jul 20. pii: S0378-1119(16)30572-8. doi: 10.1016/j.gene.2016.
    PubMed     Text format     Abstract available

    J Am Acad Dermatol

  10. MARTIRES KJ, Pomeranz MK, Stein JA, Grant-Kels JM, et al
    Pregnancy-associated melanoma (PAMM): Is there truly a worse prognosis? Would not sound alarm bells just yet....
    J Am Acad Dermatol. 2016;75:e77.
    PubMed     Text format    

    J Invest Dermatol

  11. PAVLOVA O, Fraitag S, Hohl D
    5-hydroxymethylcytosine expression in proliferative nodules arising within congenital nevi allows differentiation from malignant melanoma.
    J Invest Dermatol. 2016 Jul 22. pii: S0022-202X(16)32124.
    PubMed     Text format     Abstract available

    J Surg Oncol

  12. LIU JB, Bilimoria KY
    Weighing the value of completion nodal dissection for melanoma.
    J Surg Oncol. 2016 Jul 22. doi: 10.1002/jso.24273.
    PubMed     Text format     Abstract available

    Lancet Oncol

  13. BURKI TK
    Resistance to PD-1 blockade in melanoma.
    Lancet Oncol. 2016 Jul 21. pii: S1470-2045(16)30372.
    PubMed     Text format    

    Melanoma Res

  14. DILLER ML, Kudchadkar RR, Delman KA, Lawson DH, et al
    Complete response to high-dose IL-2 and enhanced IFNgamma+Th17 : TREG ratio in a melanoma patient.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available

  15. ENNINGA EA, Nevala WK, Holtan SG, Leontovich AA, et al
    Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma.
    Melanoma Res. 2016.
    PubMed     Text format     Abstract available


  16. BURRIS CK, Rodriguez ME, Potter HD
    Scleral Necrosis Simulating Recurrent Uveal Melanoma after Plaque Brachytherapy.
    Ophthalmology. 2016;123:1761.
    PubMed     Text format    

  17. FABIAN ID, Thaung C, Cohen VM
    Extremely Invasive Conjunctival Melanoma.
    Ophthalmology. 2016;123:1652.
    PubMed     Text format    

    PLoS One

  18. FROUIN E, Maudelonde T, Senal R, Larrieux M, et al
    Comparative Methods to Improve the Detection of BRAF V600 Mutations in Highly Pigmented Melanoma Specimens.
    PLoS One. 2016;11:e0158698.
    PubMed     Text format     Abstract available

  19. AZZARITO T, Lugini L, Spugnini EP, Canese R, et al
    Effect of Modified Alkaline Supplementation on Syngenic Melanoma Growth in CB57/BL Mice.
    PLoS One. 2016;11:e0159763.
    PubMed     Text format     Abstract available

  20. VEDEL-KROGH S, Nielsen SF, Schnohr P, Nordestgaard BG, et al
    Morbidity and Mortality in 7,684 Women According to Personal Hair Dye Use: The Copenhagen City Heart Study followed for 37 Years.
    PLoS One. 2016;11:e0151636.
    PubMed     Text format     Abstract available

  21. YUAN P, Cao JL, Abuduwufuer A, Wang LM, et al
    Clinical Characteristics and Prognostic Significance of TERT Promoter Mutations in Cancer: A Cohort Study and a Meta-Analysis.
    PLoS One. 2016;11:e0146803.
    PubMed     Text format     Abstract available

    Proc Natl Acad Sci U S A

  22. DONDOSSOLA E, Dobroff AS, Marchio S, Cardo-Vila M, et al
    Self-targeting of TNF-releasing cancer cells in preclinical models of primary and metastatic tumors.
    Proc Natl Acad Sci U S A. 2016;113:2223-8.
    PubMed     Text format     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Pfizer Oncology.